4+ day, 1+ hour ago   (209+ words) The Pharma Letter - Solstice Oncology launches with $225 million to advance neoadjuvant CTLA-4 antibody USA-based Solstice Oncology has launched with a $225 million Series A financing to advance porustobart, a second-generation, Fc-enhanced CTLA-4 antibody, into neoadjuvant treatment of colon cancer. The round…...

4+ day, 21+ hour ago   (228+ words) The Pharma Letter MannKind inks obesity deal with Rose Pharma US biopharma company MannKind Corp (Nasdaq: MNKD) and Rose Pharma today announced that they have entered into a worldwide licensing and collaboration agreement to develop ROSE-010 Technosphere for weight management....

2+ week, 5+ day ago   (235+ words) The Pharma Letter Bristol Myers ends Cellares CAR-T manufacturing deal US cell therapy manufacturing specialist Cellares is cutting jobs after losing a major pharmaceutical customer, in a setback for one of the sector's best-funded attempts to automate the production of…...

2+ week, 6+ day ago   (227+ words) The Pharma Letter - Revier launches with six million euros seed round to develop class IIa HDAC inhibitors for cardiometabolic disease German biotech Revier Therapeutics has launched operations following the close of a six million euros ($6.45 million) seed financing round, the…...

3+ week, 4+ day ago   (260+ words) The Pharma Letter - ALK appoints Jacob Glenting head of Global R&D Danish allergy specialist ALK-Abelló A/S (Nasdaq Copenhagen: ALK B) has appointed Jacob Glenting (pictured above) as executive vice president and head of global R&D, effective September…...

3+ week, 4+ day ago   (268+ words) The Pharma Letter - Network Bio launches with $50 million financing, unveils NVIDIA collab Network Bio, a Palo Alto, California-based biotechnology company building AI models trained on human biological data, launched on August 19 with $50 million in financing from investors including Section 32, Thiel…...

3+ week, 4+ day ago   (243+ words) The Pharma Letter - Kynexis raises 97 million euros to advance med for cognitive disorders Dutch clinical-stage biotech Kynexis today announced the closing of a 40 million euros ($46.3 million) Series A extension bringing total Series A financing to 97 million euros ($110 million). The financing…...

3+ week, 5+ day ago   (275+ words) The Pharma Letter - Dash Bio banks $30 million to automate development bottleneck USA-based bioanalysis firm Dash Bio has raised $30 million in a series A round led by Oak HC/FT, money it will spend on a laboratory that hands much of…...

3+ week, 5+ day ago   (212+ words) thepharmaletter.com - OmniAb signs $370 million ion channel discovery deal with Eli Lilly California-based antibody discovery technology provider OmniAb (Nasdaq: OABI) has entered a global collaboration and license agreement with US pharma major Eli Lilly (NYSE: LLY) covering a new ion…...

3+ week, 6+ day ago   (185+ words) The Pharma Letter - LEO Pharma strengthens pipeline with buy of dersimelagon Danish dermatology specialist LEO Pharma today announces that it has entered into an agreement to acquire worldwide rights to dersimelagon from Japanese drugmaker Tanabe Pharma. This article is accessible…...